Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: A retrospective study.

Abstract

The ProstateVolume 78, Issue 4 p. 278-278 LETTER TO THE EDITOR Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: A retrospective study Takeshi Azuma, Corresponding Author Takeshi Azuma tazuma-tky@umin.ac.jp orcid.org/0000-0002-4921-2122 Department of Urology, Tokyo Metropolitan Tama Medical Center Correspondence Takeshi Azuma, MD, PhD, Department of Urology, Tokyo Metropolitan Tama Medical Center, 2-9-2 Musashidai, Fuchu, Tokyo, Japan 183-0042. Email: tazuma-tky@umin.ac.jpSearch for more papers by this author Takeshi Azuma, Corresponding Author Takeshi Azuma tazuma-tky@umin.ac.jp orcid.org/0000-0002-4921-2122 Department of Urology, Tokyo Metropolitan Tama Medical Center Correspondence Takeshi Azuma, MD, PhD, Department of Urology, Tokyo Metropolitan Tama Medical Center, 2-9-2 Musashidai, Fuchu, Tokyo, Japan 183-0042. Email: tazuma-tky@umin.ac.jpSearch for more papers by this author First published: 08 January 2018 https://doi.org/10.1002/pros.23470Citations: 2Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article.Citing Literature Volume78, Issue4March 1, 2018Pages 278-278 RelatedInformation